|
Lp(a) (mg/dL)
|
Recurrent CVEs/Total
|
Crude model
|
Adjusted model
|
|---|
|
(153/2284)
|
HR (95% CI)
|
p value
|
HR (95% CI)
|
p value
|
|---|
|
Total patients
|
153/2284
| | | | |
|
Lp(a) per-SD increase
| |
1.007 (1.002–1.013)
|
0.007
|
1.008 (1.002–1.014)
|
0.006
|
|
Lp(a) < 10
|
37/846
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
59/769
|
1.736 (1.151–2.619)
|
0.009
|
1.720 (1.099–2.692)
|
0.018
|
|
Lp(a) ≥ 30
|
57/669
|
1.960 (1.296–2.965)
|
0.001
|
2.049 (1.308–3.212)
|
0.002
|
|
HBA1c < 7.0%
|
74/1146
| | | | |
|
Lp(a) per-SD increase
| |
1.008 (1.001–1.016)
|
0.024
|
1.009 (1.001–1.018)
|
0.023
|
|
Lp(a) < 10
|
17/427
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
28/373
|
1.968 (1.077–3.595)
|
0.028
|
1.815 (0.949–3.473)
|
0.072
|
|
Lp(a) ≥ 30
|
29/346
|
2.156 (1.185–3.924)
|
0.012
|
2.009 (1.051–3.840)
|
0.035
|
|
HBA1c ≥ 7.0%
|
79/1138
| | | | |
|
Lp(a) per-SD increase
| |
1.006 (0.998–1.014)
|
0.122
|
1.009 (1.000–1.018)
|
0.050
|
|
Lp(a) < 10
|
20/418
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
31/402
|
1.520 (0.866–2.667)
|
0.144
|
1.571 (0.842–2.932)
|
0.155
|
|
Lp(a) ≥ 30
|
28/318
|
1.816 (1.023–3.223)
|
0.042
|
2.162 (1.148–4.073)
|
0.017
|
- The adjusted model including age, sex, body mass index, currentis smoking, hypertension, dyslipidemia, family history of coronary artery disease, diseased vessels, low-density lipoprotein cholesterol, fasting blood glucose, statin and anti-diabetes drugs use
- CVEs cardiovascular events, MI myocardial infarction, CVD cardiovascular disease
